1877 — Shanghai Junshi Biosciences Share News
0.000.00%
Last trade - 00:00- HK$15.67bn
- HK$18.79bn
- CNY2.50bn
Brief: Shanghai Junshi Biosciences Says Unit Received Certificate Of GMP Compliance Of A Manufacturer
Brief: Shanghai Junshi Biosciences Says JS125 Received Acceptance Notice For Investigational New Drug Application By NMPA
Brief: Shanghai Junshi Biosciences Says Approval Of Supplemental New Drug Application For Toripalimab By China's NMPA
Brief: Junshi Biosciences Announces Approval Of The sNDA For Toripalimab For The 1st-Line Treatment Of Advanced TNBC
Brief: Junshi Biosciences' Board Elects Chairman
Brief: Shanghai Junshi Biosciences Says Approval Of Supplemental New Drug Application For Toripalimab By NMPA
Brief: Shanghai Junshi Biosciences Says Phase 3 Clinical Study Of Toripalimab In Combination With Bevacizumab Met Primary Endpoint
Brief: Junshi Biosciences Says Q1 Net Loss At 283.0 Mln Yuan
Brief: Shanghai Junshi Biosciences Says Drug Office In Hong Kong Accepted New Drug Application Of Toripalimab
Brief: Shanghai Junshi Says NMPA Approves Toripalimab As Treatment For Renal Cell Carcinoma
Brief: Shanghai Junshi Biosciences Says Acceptance Of Supplemental New Drug Applications By NMPA
Brief: Shanghai Junshi Biosciences's 2023 Net Loss 2.3 Bln Yuan
Brief: Shanghai Junshi Biosciences's Prelim 2023 Net Loss 2.2 Bln Yuan
Brief: Shanghai Junshi Biosciences Announces Plan To Repurchase Portion Of Its H Shares In Open Market
Brief: Shanghai Junshi Biosciences Says Singapore Health Sciences Authority Accepted New Drug Application Of Toripalimab
Brief: Shanghai Junshi Biosciences Says Technology Development Contract With Shanghai Allink Biotherapeutics
Brief: Shanghai Junshi Biosciences Sees 2023 Net Loss Of 2.3 Bln Yuan
Brief: Shanghai Junshi Biosciences Says Li Ning Elected Vice Chairman Of Third Session Of Board
Brief: Shanghai Junshi Biosciences's Board Elects Vice Chairman